Stockreport

U.S. Food and Drug Administration Accepts for Priority Review Deciphera's New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) [Yaho...

ONO PHARM CO UNSP/ADR  (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
PDF The U.S. FDA has assigned a target action date of February 17, 2025 EMA has accepted Deciphera's a Marketing Authorization Application for vimseltinib OSAKA, Japan [Read more]